World takes stock of COVID-19 drug


SEOUL/BERLIN/LONDON: Some governments in Europe and Asia said on Wednesday they have enough of Gilead’s COVID-19 anti-viral remdesivir for now despite fears of shortages since the U.S. drugmaker pledged most output to its home market for the next three months. The pharmaceutical company’s move stirred the global debate about equitable access to drugs and brought concerns about accessibility, especially in regions where coronavirus rates are still high or there have been new outbreaks.